 | |
| Clinical data | |
|---|---|
| ATC code |
|
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider |
|
| UNII | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C12H16F3NS |
| Molar mass | 263.32 g·mol−1 |
| 3D model (JSmol) | |
| Chirality | Racemic mixture |
| |
| |
 N Y (what is this?) (verify) | |
Tiflorex (TFX), formerly known asflutiorex, is astimulant[citation needed]amphetamine that was under development as anappetite suppressant in the 1970s,[1][2] but appears to have been abandoned. It isstructurally related tofenfluramine and4-MTA.
Tiflorex went to phase II clinical trials. Theextended release formulation "TFX-SR" produced significant suppression of appetite. It also caused slightly more sleep disturbances andheadaches than placebo, as well asmydriasis and a self-reporteddecrease in arousal. It had little effect onheart rate.[2]
Tifluorex is claimed to be a more potent anorectic than fenfluramine, with twice its potency in humans[2] and 4 times its potency in rats.[3]
The mechanism of action of tiflorex has apparently never been studied. Similar compounds such asfenfluramine,norfenfluramine and4-MTA act asselective serotonin releasing agents and5-HT2 receptor agonists. Fenfluramine in particular causes very similar side effects and appetite suppression at therapeutically relevant doses.
In rats, tiflorex is rapidlyN-dealkylated tonorflutiorex. Both tiflorex and norflutiorex appear to be excreted in urine.[1]
TheRosenmund reduction of 3-(trifluoromethylthio)benzoyl chloride [51748-28-8] (1) gave 3-((trifluoromethyl)thio)benzaldehyde [51748-27-7] (2).Henry reaction with nitroethane led to 1-(2-nitroprop-1-en-1-yl)-3-[(trifluoromethyl)sulfanyl]benzene [176242-84-5] (3). With the aid of iron catalyst in concentrated HCl acid there occurred FGI into 1-(3'-trifluoromethylthiophenyl)-2-propanone,CID:21325269 (4'). Reductive amination withethylamine andformic acid as the reductant completed the synthesis of tiflorex (5).
